Alder Therapeutics announced that it has received SEK 20 million in seed round of funding co-led by new investors Flerie Invest AB and Linc AB on September 27, 2022. Upon the completion, the company will receive an additional SEK 14.4 million co-investment, also equally split between Linc and Flerie Invest. Linc's and Flerie Invest's ownership will be 29% following the initial seed funding
round. Following the potential additional investment round the ownership would be 41%.